Kalehua Capital Management LLC — 13F Holdings & Portfolio
CIK 2106181 · latest 13F-HR filed 2026-08-14
Kalehua Capital Management LLC manages $139.5M in 13F-reported U.S. long-equity assets across 23 reported positions as of its 2026-06-30 13F-HR filing. Its largest disclosed positions are MANE (12.84%), XFOR (12.46%), CMPS (8.31%). Quarter over quarter (versus its 2026-03-31 filing) the fund opened 7 new positions and exited 7; 9 existing positions rose in reported value and 5 fell.
AUM is the long-equity portion reported on Form 13F-HR. Excludes short positions, cash, foreign holdings, and non-13F assets. For informational purposes only — not investment advice.
Long-equity book
Distinct positions
Filed 2026-08-14
vs 2026-03-31
Portfolio charts
Latest quarter's book, what changed, and how the portfolio has evolved across filings.
| Name | Title / Status | Ownership | Type |
|---|
Quarter-over-quarter changes
Changes in reported position value vs the prior 13F, so price moves count too, not just shares bought or sold.
Top Adds (vs prior quarter)
- Veradermics Inc$11.4M +175.7%
- Compass Pathways Plc$7.1M +155.9%
- Aclaris Therapeutics Inc$4.7M +93.3%
- Inhibikase Therapeutics Inc$3.3M +72.8%
- X4 Pharmaceuticals Inc$2.0M +13.1%
Top Trims
- Surrozen Inc-$1.2M -10.9%
- Gossamer Bio Inc-$619.3K -25.2%
- Tyra Biosciences Inc-$473.6K -16.6%
- LeonaBio Inc-$429.1K -10.6%
- Instil Bio Inc-$386.4K -33.5%
New Positions
- Karyopharm Therapeutics Inc$6.7M
- Inflarx Nv$6.5M
- Cyclerion Therapeutics Inc$5.6M
- Nuvectis Pharma Inc$1.8M
- Milestone Pharmaceuticals Inc$1.7M
Exited Positions
- Alpha Architect 1-3 Month Box ETF$13.8M
- Relay Therapeutics Inc$9.0M
- Oruka Therapeutics Inc$5.8M
- Tenaya Therapeutics Inc$1.4M
- PepGen Inc$1.3M
Kalehua Capital Management LLC Holdings (2026-06-30)
Rows tagged Call or Put are options positions, not stock. Per SEC Form 13F-HR, Value shows the notional value of the underlying (shares covered × underlying price), not the option premium. Shares is the number of underlying shares covered (divide by 100 for contract count).
| # | Issuer | Symbol | CUSIP | Value | Weight | Shares | Type |
|---|---|---|---|---|---|---|---|
| 1 | Veradermics Inc | MANE | 922967104 | $17.9M | 12.84% | 145,695 | SH |
| 2 | X4 Pharmaceuticals Inc | XFOR | 98420X202 | $17.4M | 12.46% | 3,722,840 | SH |
| 3 | Compass Pathways Plc | CMPS | 20451W101 | $11.6M | 8.31% | 819,692 | SH |
| 4 | Surrozen Inc | SRZN | 86889P208 | $10.0M | 7.16% | 385,178 | SH |
| 5 | Aclaris Therapeutics Inc | ACRS | 00461U105 | $9.7M | 6.95% | 1,832,365 | SH |
| 6 | Sionna Therapeutics Inc | SION | 829401108 | $8.7M | 6.21% | 197,072 | SH |
| 7 | Inhibikase Therapeutics Inc | IKT | 45719W205 | $7.8M | 5.56% | 3,821,890 | SH |
| 8 | Pharvaris NV | PHVS | N69605108 | $6.9M | 4.93% | 198,772 | SH |
| 9 | Karyopharm Therapeutics Inc | KPTI | 48576U205 | $6.7M | 4.80% | 685,644 | SH |
| 10 | Septerna Inc | SEPN | 81734D104 | $6.5M | 4.67% | 194,544 | SH |
| 11 | Inflarx Nv | IFRX | N44821101 | $6.5M | 4.65% | 2,897,769 | SH |
| 12 | Cyclerion Therapeutics Inc | CYCN | 23255M204 | $5.6M | 4.01% | 1,651,350 | SH |
| 13 | Uniqure Nv | QURE | N90064101 | $3.7M | 2.62% | 79,407 | SH |
| 14 | LeonaBio Inc | LONA | 04746L203 | $3.6M | 2.59% | 393,701 | SH |
| 15 | Damora Therapeutics Inc | DMRA | 36322Q206 | $3.6M | 2.59% | 139,000 | SH |
| 16 | MoonLake Immunotherapeutics | MLTX | 61559X104 | $3.4M | 2.45% | 175,734 | SH |
| 17 | Tyra Biosciences Inc | TYRA | 90240B106 | $2.4M | 1.70% | 74,465 | SH |
| 18 | Nuvectis Pharma Inc | NVCT | 67080T108 | $1.8M | 1.32% | 100,000 | SH |
| 19 | Gossamer Bio Inc | GOSS | 38341P102 | $1.8M | 1.32% | 11,149,363 | SH |
| 20 | Milestone Pharmaceuticals Inc | MIST | 59935V107 | $1.7M | 1.22% | 1,269,237 | SH |
| 21 | Atyr Pharma Inc | ATYR | 002120202 | $1.1M | 0.76% | 1,788,167 | SH |
| 22 | Instil Bio Inc | TIL | 45783C200 | $765.9K | 0.55% | 99,600 | SH |
| 23 | Tscan Therapeutics Inc | TCRX | 89854M101 | $445.8K | 0.32% | 454,876 | SH |
| Period | Filed | AUM | Holdings | Accession |
|---|---|---|---|---|
| 2026-06-30 | 2026-08-19 | $174.0M | 26 | 0002106181-26-000008 |
| 2026-06-30 | 2026-08-14 | $139.5M | 23 | 0002106181-26-000007 |
| 2026-03-31 | 2026-05-15 | $141.3M | 27 | 0002106181-26-000005 |
| 2026-03-31 | 2026-05-15 | $118.6M | 23 | 0002106181-26-000004 |
| 2025-12-31 | 2026-02-13 | $101.1M | 19 | 0002106181-26-000003 |
DALLAS, TX 75219